Report of Foreign Issuer (6-k)
25 September 2017 - 9:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of
September 2017
Commission File Number
000-50112
RepliCel Life Sciences Inc.
(Translation of registrant’s name
into English)
Suite 900 - 570 Granville Street,
Vancouver, British Columbia V6C 3P1
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ☐
Note:
Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security
holders.
SUBMITTED HEREWITH
99.1 News Release dated
September 22, 2017 - RepliCel Retains Hybrid Financial for Investor Relations
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
RepliCel Life Sciences Inc.
/s/ Lee Buckler
Lee Buckler, President
Date: September 22, 2017
3
RepliCel Life Sciences (PK) (USOTC:REPCF)
Historical Stock Chart
From Apr 2024 to May 2024
RepliCel Life Sciences (PK) (USOTC:REPCF)
Historical Stock Chart
From May 2023 to May 2024